When I was diagnosed with Parkinson’s in August 2019, a doctor told me that Sinemet (Levodopa/Carbidopa), the starter drug of ...

The origin of many diseases such as Alzheimer's or Parkinson's can be found at the molecular level in our body, in other ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson’s Disease (“PD”) and Hepion ...

The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

In the United States, out-of-pocket (OOP) costs of brand-name medications for neurological ... and 45,909 with Parkinson’s ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Early initiation of pimavanserin among patients with Parkinson disease psychosis were more likely to experience complete symptom resolution.

Research led by the University of Michigan has provided compelling evidence that could solve a fundamental mystery in the makeup of fibrils that play a role in Alzheimer's, Parkinson's and other ...

A new study shows that a common glaucoma drug cleared tau build-up and reduced signs of neurodegenerative disease in zebrafish and mice.